Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
161-180 of 936 trials

Non-Hodgkin Lymphoma: Epcoritamab with Anti-Cancer Agents

We are studying the safety and tolerability of Epcoritamab combined with other anti-cancer medications for people with Non-Hodgkin Lymphoma. This trial aims to see how well this combination works and to find the best dose for future studies.

B-cell Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Solid Tumors: JNJ-87890387

We are testing a new treatment called JNJ-87890387 for patients with advanced solid tumors. The goal is to understand its safety and how it works in the body.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Myotonic Dystrophy Type 1: ATX-01 Treatment Study

We are evaluating the safety and effects of ATX-01 in adults with myotonic dystrophy type 1. The study aims to see how it impacts muscle function and daily living activities.

Myotonic Dystrophy6-12 monthsSafety phase (I)Post-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Advanced Solid Tumors: M1774 and PLX038 Combination

We are investigating whether a new oral medication combined with another drug can help patients with advanced solid tumors. This study aims to explore the effectiveness of this treatment approach.

Metastatic Triple Negative Breast Cancer>2 yearsSafety phase (I)Oncology

Blood Cancer Treatment: ABBV-319 Study

We are examining how a new intravenous treatment affects adults with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia. The study looks at potential side effects and changes in disease activity.

Follicular LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell Lymphoma>2 yearsSafety phase (I)Oncology

B-cell Non-Hodgkin Lymphoma: CARCIK-CD19 Cell Therapy

We are studying a new cell therapy for adults and children with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The trial aims to evaluate the safety and effectiveness of this treatment.

B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Metastatic Colorectal Cancer: LB-100 and Atezolizumab Study

We are investigating a new combination of medications for patients with metastatic colorectal cancer to see if it is safe and effective. This study aims to find the best dose and understand how well the treatment works.

Microsatellite Stable Colorectal Cancer>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

CALR-Mutated Myeloproliferative Neoplasms: JNJ-88549968 Study

We are testing a new T-cell redirecting antibody for patients with CALR-mutated myeloproliferative neoplasms. This study aims to evaluate its safety and potential effectiveness in treating this condition.

CALR-mutated Myeloproliferative Neoplasms>2 yearsSafety phase (I)HematologyOncology

Kidney Cancer: New Treatment Study

We are investigating a new treatment option for individuals diagnosed with kidney cancer. The goal is to see if this treatment can improve outcomes compared to standard care.

Metastatic Renal Cell Carcinoma with End-Stage Renal Disease>2 yearsSafety phase (I)Efficacy phase (II)Oncology

B-Cell Non-Hodgkin’s Lymphoma: Glofitamab and Obinutuzumab Study

We are studying the safety and effectiveness of Glofitamab alone and with Obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This trial aims to find the best dose and understand how these treatments work together.

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Metastatic Neuroendocrine Prostate Cancer: Targeted Radioligand Therapy

We are exploring a new targeted treatment for patients with metastatic neuroendocrine prostate cancer. This study aims to assess its safety and effectiveness compared to existing therapies.

Metastatic Neuroendocrine Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Fosigotifator for Vanishing White Matter Disease

We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.

Vanishing White Matter Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Mild Age-Related Hearing Loss: DX243 Treatment

We are testing a new treatment for people with mild age-related hearing loss to see if it is safe and effective. The study starts with healthy volunteers before moving to patients.

Age-Related Hearing Loss>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineOtolaryngology

Severe Hemophilia A: Efanesoctocog Alfa Study

We are comparing a new treatment, efanesoctocog alfa, with other existing therapies for severe hemophilia A. This study aims to understand how well it works in managing the condition.

Haemophilia A1-2 yearsSafety phase (I)Hematology

Acute Myeloid Leukemia: MB-dNPM-1-TCR.1 Treatment

We are studying a new therapy for patients with relapsed or refractory acute myeloid leukemia. The goal is to understand its safety and how well it works compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Acute Myeloid Leukemia: Emavusertib Treatment Study

We are testing a new drug, Emavusertib, for patients with acute myeloid leukemia who still have traces of the disease while on other treatments. The goal is to see if it improves their condition.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Oncology

B-Cell Acute Lymphoblastic Leukemia: AZD0486 Study

We are investigating whether AZD0486 is safe and effective for adolescents and adults with relapsed or refractory B-cell acute lymphoblastic leukemia. This trial aims to understand how well it works compared to existing treatments.

B-Cell Acute Lymphoblastic LeukaemiaSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Juvenile Idiopathic Arthritis: Filgotinib Study

We are studying how the medication filgotinib works in children and teens with juvenile idiopathic arthritis. The trial will also evaluate its safety and how well young patients accept the medication.

Juvenile Idiopathic Arthritis≤3 monthsSafety phase (I)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPediatricsRheumatology

Advanced Solid Tumors: PF-08046050 Study

We are investigating a new treatment for adults with advanced solid tumors. This study aims to understand how well it works compared to current options.

Small Cell Lung CancerPancreatic CarcinomaColorectal Cancer>2 yearsSafety phase (I)Oncology

Advanced Neuroendocrine Cancers: DAREON™-7 Study

We are testing how well different doses of BI 764532 work with chemotherapy for people with advanced neuroendocrine cancers. The goal is to see which doses are best tolerated by patients.

Neuroendocrine CarcinomaExtra-pulmonary Neuroendocrine CarcinomaPulmonary Large Cell Neuroendocrine Carcinoma>2 yearsSafety phase (I)Oncology